Spectranetics To Present At The Canaccord Genuity Cardiovascular, Aesthetics & Metabolic Disorders Conference On December 6
Spectranetics Corporation (Nasdaq: SPNC) today announced that it
will present at the 6
th Annual Canaccord Genuity
Cardiovascular, Aesthetics and Metabolic Disorders Conference being held
Tuesday, December 6, 2011, at...
Spectranetics Corporation (Nasdaq: SPNC) today announced that it will present at the 6 th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference being held Tuesday, December 6, 2011, at the Nikko Hotel in San Francisco. Scott Drake, Spectranetics’ chief executive officer, is scheduled to speak at 11:20 a.m. Pacific time (2:20 p.m. Eastern time). Interested parties can access a live audio webcast at www.spectranetics.com. An archived presentation will be available on the Web site for 30 days. About Spectranetics Spectranetics develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are sold in more than 40 countries and are used to treat arterial blockages in the heart and legs as well as the removal of pacemaker and defibrillator leads. The Company’s Vascular Intervention (VI) products include a range of peripheral and cardiac laser catheters for ablation of occluded arteries above and below the knee and within coronary arteries. The Company also markets aspiration and thrombectomy catheters for the removal of thrombus and support catheters to facilitate crossing of coronary and peripheral arterial blockages. The Lead Management (LM) product line includes excimer laser sheaths and cardiac lead management accessories for the removal of pacemaker and defibrillator cardiac leads. For more information, visit www.spectranetics.com.